FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W951303760> ?p ?o ?g. }

• W951303760 endingPage "627" @default.
• W951303760 startingPage "617" @default.
• W951303760 abstract "In Brief OBJECTIVE: To assess whether add-back therapy with norethindrone acetate or norethindrone acetate plus conjugated equine estrogens is superior to maintain bone health in adolescents and young women using gonadotropin-releasing hormone agonists for endometriosis. Gonadotropin-releasing hormone agonists are associated with deleterious effects on bone. Hormonal add-back may mitigate these effects. METHODS: Adolescents and young women (n=51) received a random, double-blind assignment to add-back with norethindrone acetate (5 mg/day) plus conjugated equine estrogens (0.625 mg/day) or norethindrone acetate plus placebo for 12 months. Body composition, bone mineral content, and bone mineral density (BMD) were obtained by dual-energy X-ray absorptiometry every 6 months. Quality-of-life measures were collected every 3 months. Intention-to-treat comparison of outcomes was conducted by repeated-measures analysis of variance. RESULTS: Thirty-four adolescents and young women completed the trial; dropouts did not differ from those who completed the trial. Bone mineral density was normal at baseline. At 12 months, total body bone mineral content and BMD had increased in the norethindrone acetate plus conjugated equine estrogens group (bone mineral content +37 g, P<.001 and BMD +0.012 g/cm2, P=.05), but not in those receiving norethindrone acetate plus placebo (bone mineral content P=.19 and BMD P=.95). Lean mass increased only in those receiving conjugated equine estrogens (+1.4 kg, P=.001). Improvements in physical functioning domains of quality-of-life assessments were greater with norethindrone acetate plus conjugated equine estrogens (P=.005). No differences were seen at the hip or lumbar spine by dual-energy X-ray absorptiometry. No significant adverse events occurred. CONCLUSION: Hormonal add-back successfully preserved bone health and improved quality of life for adolescents and young women with endometriosis during 12 months of gonadotropin-releasing hormone agonist therapy. Combination norethindrone acetate plus conjugated equine estrogens add-back appears to be more effective for increasing total body bone mineral content, areal BMD, and lean mass than norethindrone acetate monotherapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; www.clinicaltrials.gov, NCT00474851. LEVEL OF EVIDENCE: I Oral norethindrone acetate plus estrogen add-back therapy appears to safely increase areal bone mineral density and bone mineral content in females with endometriosis during 1 year of gonadotropin-releasing hormone agonist treatment." @default.
• W951303760 created "2016-06-24" @default.
• W951303760 creator A5005934043 @default.
• W951303760 creator A5016675740 @default.
• W951303760 creator A5019568309 @default.
• W951303760 creator A5025035372 @default.
• W951303760 creator A5048250013 @default.
• W951303760 creator A5065575169 @default.
• W951303760 creator A5069056708 @default.
• W951303760 date "2015-09-01" @default.
• W951303760 modified "2023-10-10" @default.
• W951303760 title "Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis" @default.
• W951303760 cites W1990060114 @default.
• W951303760 cites W2004736488 @default.
• W951303760 cites W2008316410 @default.
• W951303760 cites W2022187355 @default.
• W951303760 cites W2026056052 @default.
• W951303760 cites W2041440843 @default.
• W951303760 cites W2045807575 @default.
• W951303760 cites W2054703956 @default.
• W951303760 cites W2055721302 @default.
• W951303760 cites W2068643120 @default.
• W951303760 cites W2090062039 @default.
• W951303760 cites W2100058472 @default.
• W951303760 cites W2132718347 @default.
• W951303760 cites W2133150780 @default.
• W951303760 cites W2144226947 @default.
• W951303760 cites W2145626263 @default.
• W951303760 cites W2153059487 @default.
• W951303760 cites W2154443166 @default.
• W951303760 cites W2168382554 @default.
• W951303760 doi "https://doi.org/10.1097/aog.0000000000000964" @default.
• W951303760 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4545413" @default.
• W951303760 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26181088" @default.
• W951303760 hasPublicationYear "2015" @default.
• W951303760 type Work @default.
• W951303760 sameAs 951303760 @default.
• W951303760 citedByCount "53" @default.
• W951303760 countsByYear W9513037602015 @default.
• W951303760 countsByYear W9513037602016 @default.
• W951303760 countsByYear W9513037602017 @default.
• W951303760 countsByYear W9513037602018 @default.
• W951303760 countsByYear W9513037602019 @default.
• W951303760 countsByYear W9513037602020 @default.
• W951303760 countsByYear W9513037602021 @default.
• W951303760 countsByYear W9513037602022 @default.
• W951303760 countsByYear W9513037602023 @default.
• W951303760 crossrefType "journal-article" @default.
• W951303760 hasAuthorship W951303760A5005934043 @default.
• W951303760 hasAuthorship W951303760A5016675740 @default.
• W951303760 hasAuthorship W951303760A5019568309 @default.
• W951303760 hasAuthorship W951303760A5025035372 @default.
• W951303760 hasAuthorship W951303760A5048250013 @default.
• W951303760 hasAuthorship W951303760A5065575169 @default.
• W951303760 hasAuthorship W951303760A5069056708 @default.
• W951303760 hasBestOaLocation W9513037602 @default.
• W951303760 hasConcept C126322002 @default.
• W951303760 hasConcept C134018914 @default.
• W951303760 hasConcept C142724271 @default.
• W951303760 hasConcept C204787440 @default.
• W951303760 hasConcept C27081682 @default.
• W951303760 hasConcept C2776541429 @default.
• W951303760 hasConcept C2776886416 @default.
• W951303760 hasConcept C2779329777 @default.
• W951303760 hasConcept C71924100 @default.
• W951303760 hasConceptScore W951303760C126322002 @default.
• W951303760 hasConceptScore W951303760C134018914 @default.
• W951303760 hasConceptScore W951303760C142724271 @default.
• W951303760 hasConceptScore W951303760C204787440 @default.
• W951303760 hasConceptScore W951303760C27081682 @default.
• W951303760 hasConceptScore W951303760C2776541429 @default.
• W951303760 hasConceptScore W951303760C2776886416 @default.
• W951303760 hasConceptScore W951303760C2779329777 @default.
• W951303760 hasConceptScore W951303760C71924100 @default.
• W951303760 hasIssue "3" @default.
• W951303760 hasLocation W9513037601 @default.
• W951303760 hasLocation W9513037602 @default.
• W951303760 hasLocation W9513037603 @default.
• W951303760 hasOpenAccess W951303760 @default.
• W951303760 hasPrimaryLocation W9513037601 @default.
• W951303760 hasRelatedWork W2044054235 @default.
• W951303760 hasRelatedWork W2055260481 @default.
• W951303760 hasRelatedWork W2077750254 @default.
• W951303760 hasRelatedWork W2079635857 @default.
• W951303760 hasRelatedWork W2081570904 @default.
• W951303760 hasRelatedWork W2084548911 @default.
• W951303760 hasRelatedWork W2108408273 @default.
• W951303760 hasRelatedWork W2115470487 @default.
• W951303760 hasRelatedWork W2119482358 @default.
• W951303760 hasRelatedWork W2171929497 @default.
• W951303760 hasVolume "126" @default.
• W951303760 isParatext "false" @default.
• W951303760 isRetracted "false" @default.
• W951303760 magId "951303760" @default.
• W951303760 workType "article" @default.